Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061800 | 0.89 | CA2 (0.44) | PTGS2KMT2ANPC1ALDH1A1HSD17B10 | |
| SCHEMBL11690780 | 0.85 | PTGS2 (0.55) | PTGS2KMT2ANPC1ALDH1A1CA2 | |
| SCHEMBL23691266 | 0.83 | ALDH1A1 (0.44) | KMT2ANPC1ALDH1A1HSD17B10TDP1 | |
| SCHEMBL11582128 | 0.83 | ALDH1A1 (0.52) | KMT2AALDH1A1HSD17B10TDP1CA2 | |
| SCHEMBL3059014 | 0.80 | RECQL (0.60) | ALDH1A1HSD17B10TDP1CA2RECQL | |
| SCHEMBL617094 | 0.79 | CA2 (0.64) | PTGS2KMT2AALDH1A1HSD17B10TDP1 | |
| SCHEMBL16273105 | 0.78 | KMT2A (0.71) | KMT2ANPC1ALDH1A1TDP1CA2 | |
| SCHEMBL14610271 | 0.78 | GFER (0.58) | KMT2AALDH1A1TDP1CA2RECQL | |
| SCHEMBL27423912 | 0.78 | CA2 (0.48) | PTGS2KMT2AALDH1A1CA2CA12 | |
| SCHEMBL2044233 | 0.77 | RECQL (0.67) | PTGS2ALDH1A1TDP1CA2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| EP-1243583-B1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | EISAI CO LTD (JP) | 2005-09-28 | — | — | EP | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-6787534-B2 | SUBSTITUTED QUINOLINE AND ISOQUINOLINE ANTIANGIOGENIC AGENTS; SULFONYLUREAS | EISAI CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-0673937-B1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | EISAI CO LTD (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1243583-A1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | Eisai Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | PTGS2 3358/4885KMT2A 2009/4885NPC1 3249/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | PTGS2 3358/4885KMT2A 2009/4885NPC1 3249/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | PTGS2 3295/4885KMT2A 2523/4885NPC1 2415/4885 |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | SLC5A2, SLC5A1, CBR3 | PTGS2 2156/4885KMT2A 1187/4885NPC1 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.